| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10910856 | Lung Cancer | 2015 | 7 Pages |
Abstract
A small (mean 10%) but significant decline in lung volumes and DLCO was recorded after SABR, with clinical impact of such change difficult to estimate in individual patients. Global QoL was not significantly impaired. Dose-volume parameters did not emerge as significantly predictive of any clinical, radiological or functional toxicity.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Cinzia Ferrero, Serena Badellino, Andrea Riccardo Filippi, Luana Focaraccio, Matteo Giaj Levra, Mario Levis, Francesco Moretto, Roberto Torchio, Umberto Ricardi, Silvia Novello,